167 related articles for article (PubMed ID: 34570596)
1. The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial.
Curtis JR; Cofield SS; Bridges SL; Bassler J; Deodhar A; Ford TL; Huffstutter J; Jankeel A; Kivitz A; Kamal S; Lindsey S; Messaoudi I; Mendoza N; Michaud K; Mikuls TR; Ridley D; Shergy W; Siegel SAR; Winthrop KL
Ann Intern Med; 2021 Nov; 174(11):1510-1518. PubMed ID: 34570596
[TBL] [Abstract][Full Text] [Related]
2. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Winthrop KL; Wouters AG; Choy EH; Soma K; Hodge JA; Nduaka CI; Biswas P; Needle E; Passador S; Mojcik CF; Rigby WF
Arthritis Rheumatol; 2017 Oct; 69(10):1969-1977. PubMed ID: 28845577
[TBL] [Abstract][Full Text] [Related]
3. Immune response and reactogenicity of intradermal administration versus subcutaneous administration of varicella-zoster virus vaccine: an exploratory, randomised, partly blinded trial.
Beals CR; Railkar RA; Schaeffer AK; Levin Y; Kochba E; Meyer BK; Evans RK; Sheldon EA; Lasseter K; Lang N; Weinberg A; Canniff J; Levin MJ
Lancet Infect Dis; 2016 Aug; 16(8):915-22. PubMed ID: 27061887
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z
Clin Infect Dis; 2017 Oct; 65(7):1174-1182. PubMed ID: 29126292
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of live varicella zoster vaccine in diabetes: a randomized, double-blind, placebo-controlled trial.
Hata A; Inoue F; Hamamoto Y; Yamasaki M; Fujikawa J; Kawahara H; Kawasaki Y; Honjo S; Koshiyama H; Moriishi E; Mori Y; Ohkubo T
Diabet Med; 2016 Aug; 33(8):1094-101. PubMed ID: 26605507
[TBL] [Abstract][Full Text] [Related]
8. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
J Virol; 2021 May; 95(12):. PubMed ID: 33762414
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
[TBL] [Abstract][Full Text] [Related]
10. Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis.
Koh JH; Lee J; Kim SH; Kwok SK; Ju JH; Park SH
J Rheumatol; 2018 Apr; 45(4):465-469. PubMed ID: 29419465
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
Weinberg A; Pang L; Johnson MJ; Caldas Y; Cho A; Tovar-Salazar A; Canniff J; Schmader KE; Popmihajlov Z; Levin MJ
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092579
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
14. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
[TBL] [Abstract][Full Text] [Related]
16. Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.
Mok CC; Chan KH; Ho LY; Fung YF; Fung WF; Woo PCY
Ann Rheum Dis; 2019 Dec; 78(12):1663-1668. PubMed ID: 31530556
[TBL] [Abstract][Full Text] [Related]
17. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
18. Disseminated varicella zoster virus infection following live attenuated herpes zoster vaccine: descriptive analysis of reports to Australia's spontaneous vaccine pharmacovigilance system, 2016-2020.
Li-Kim-Moy J; Phillips A; Morgan A; Glover C; Jayasinghe S; Hull BP; Dey A; Beard FH; Hickie M; Macartney K
BMJ Open; 2023 Jan; 13(1):e067287. PubMed ID: 36707120
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.
Wolff E; Widgren K; Scalia Tomba G; Roth A; Lep T; Andersson S
PLoS One; 2021; 16(5):e0251644. PubMed ID: 33984060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
